Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CISS vs ABEO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABEO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

ABEO Overall Winner 6-Pillar Tally: CISS 3 – 3 ABEO Matrix Metrics: CISS 4 – 6 ABEO

As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over C3is Inc. (CISS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CISS carries a Unified Composite Score of 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin), whereas ABEO carries 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin).

  • Technical & Structure Timing Caution: CISS is currently in a Breakdown options structure phase (RSI 53.6); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CISS vs ABEO
CISS NASDAQ
C3is Inc. Common Stock
Deep Sea Foreign Transportation Of Freight
$1.23
+4.24% 1D
Market Cap $991,199
TTM Revenue $36.2B
Forward P/E N/M
Beta / 30D Vol 11.91β · 1054% Vol
Unified Composite Score
33.6 / 100 SELL
Tech 5.0 Fund 29.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $1.05 · SMA50: $0.95
ABEO NASDAQ Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.42
-1.22% 1D
Market Cap $167.4M
TTM Revenue $39M
Forward P/E 18.7x
Beta / 30D Vol 0.60β · 149% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 60.0 Fund 61.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.9%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $3.39 · SMA50: $4.38

6-Pillar Scorecard Institutional Category Breakdown (CISS 3 – 3 ABEO)

Columns: Metric · CISS · ABEO
1. Valuation Multiples ABEO
Forward P/E N/M 18.7x
Trailing P/E N/M 18.7x
PEG Ratio N/M N/M
EV / Revenue N/M 3.0x
2. Growth & Scale ABEO
Revenue Growth (YoY) +249.0% +2745.0%
Earnings Growth (YoY) +193.3% +0.0%
TTM Revenue (USD) $36.2B $39M
Market Cap $991,199 $167.4M
3. Profitability & Quality CISS
Gross Margin 68.1% -3.5%
Operating Margin 24.6% -186.1%
Net Profit Margin 27.4% -160.3%
Return on Equity (ROE) 17.1% -42.1%
4. Balance Sheet & Cash Flow CISS
Cash Generation (TTM) $13.4B EBITDA -$66M
Cash Flow Margin 36.9% EBITDA Mgn N/A
Net Cash / Leverage $384.31 Book/Sh · 17.1% ROE $50M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABEO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 165.8% (27th %ile)
Put/Call OI Skew N/A 0.26x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CISS
OpEx & R&D Intensity 43.5% of Rev ($15.8B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Marine Shipping Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CISS (4) vs ABEO (6)
Institutional Metric CISS ABEO Criterion Row Edge
Market Capitalization
Scale
$991,199 $167.4M Larger Scale ABEO
Trailing P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Forward P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Revenue Growth (YoY)
Growth
+249.0% +2745.0% Higher Growth ABEO
Operating Margin (TTM)
Profitability
24.6% -186.1% Higher Margin CISS
Net Profit Margin
Profitability
27.4% -160.3% Higher Margin CISS
Return on Equity (ROE)
Capital Efficiency
17.1% -42.1% Higher ROE CISS
52-Week Range Position
Momentum
20% ($0–$6) 6% ($2–$8) Stronger Trend CISS
Beta / 30D Volatility
Risk Regime
11.91β · 1054% Vol 0.60β · 149% Vol Lower Realized Risk ABEO
Unified Institutional Score
Composite Signal
33.6 / 100 (SELL) 49.9 / 100 (HOLD) Higher Composite ABEO
Trailing 12M Revenue (USD)
Operating Scale
$36.2B $39M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.1% -3.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$13.4B EBITDA ($384.31 Book/Sh · 17.1% ROE) -$66M ($50M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CISS +181.09 pp
CISS: +135.23% · ABEO: -45.86%
3M Horizon CISS +7.2 pp
CISS: -52.87% · ABEO: -60.07%
6M Horizon CISS +7.63 pp
CISS: -47.88% · ABEO: -55.51%
1Y Horizon CISS +16.93 pp
CISS: -25.45% · ABEO: -42.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CISS Revenue ABEO Revenue CISS Op. Margin ABEO Op. Margin Margin Leader
FY2017 N/A $0M N/A -3325.7% ABEO
FY2018 N/A $0M N/A -1940.2% ABEO
FY2020 N/A $10M N/A -814.2% ABEO
FY2021 N/A $0M N/A -2994.5% ABEO
FY2022 N/A $0M N/A -3600.8% ABEO
FY2023 $30M $0M 36.3% -1346.7% CISS
FY2024 $40M N/A 23.8% N/A CISS
FY2025 $30M $10M 3.9% -1536.9% CISS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CISS BREAKDOWN
64d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CISS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABEO BREAKDOWN
71d in phase · OBV NEUTRAL
Current IV 165.8%
IV Percentile 27th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CISS Moat Profile Scale & Operating Efficiency Moat
Marine Shipping Operator
Competes within the Marine Shipping value chain with $991,199 market capitalization and 24.6% operating margin.
OpEx & R&D Reinvestment 43.5% of Rev ($15.8B)
90D Engineering Disclosures 0 Published
ABEO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $167.4M market capitalization and -186.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CISS vs ABEO Key Questions & Quantitative Answers

As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over C3is Inc. (CISS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CISS carries a Unified Composite Score of 33.6/100 (SELL) at $1.23 (N/M Forward P/E, 24.6% operating margin), whereas ABEO carries 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin). Technical & Structure Timing Caution: CISS is currently in a Breakdown options structure phase (RSI 53.6); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABEO leads the Growth & Scale pillar: CISS posts +249.0% YoY revenue growth and +193.3% YoY earnings growth on $36.2B TTM revenue (68.1% gross margin, 24.6% operating margin), compared with ABEO at +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), CISS cumulative revenue shifted +0.0% while ABEO shifted +0.0%. In operating R&D and SG&A reinvestment, CISS deploys 43.5% of Rev ($15.8B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABEO.

ABEO screens cheaper on headline valuation multiples. CISS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (36.9% EBITDA margin), whereas ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 3.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CISS (17.1% ROE) versus ABEO (-42.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CISS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (11.91β · 1054% Vol realized risk). By comparison, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.